Étiquette : phytocannabinoïdes

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L. Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L. Boggs, Jacques D. Nguyen, Daralyn Morgenson, Michael A. Taffe and Mohini Ranganathan Neuropsychopharmacology. 2018 Jan; 43(1): 142–154. Published online 2017 Oct 18. Prepublished online 2017 Sep 6. doi: 10.1038/npp.2017.209 PMCID: PMC5719112 PMID: 28875990 Abstract The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for [...]

Lire la suite

Cannabidiol provides viable treatment opportunity for multiple neurological pathologies of autism spectrum disorder, Bin Gu, 2017

Cannabidiol provides viable treatment opportunity for multipleneurological pathologies of autism spectrum disorder Bin Gu Global Drugs and Therapeutics, Review article, 2017, 2, 6, 1-4 doi: 10.15761/GDT.1000134   Abstract Autism spectrum disorder (ASD)is a heterogeneous neurodevelopmental disorderaffecting over 1% of the general population. While it is well established that ASD stems from a combination of genetic and environmental factors, there are no defined mechanisms of pathogenesis, rendering curative therapy very difficult to establish. No effective therapy exists for ASD, presenting an urgent clinical need for better control of common core pathologies of ASD regardless of its etiology. Cannabidiol (CBD), a major phytocannabinoid constituent of the cannabis plant, is [...]

Lire la suite

Les Phyto-cannabinoïdes Non-psychotropes : Les nouvelles Opportunités d’une plante ancienne, Angelo A. Izzo, Raphael Mechoulam et al., 2009

Les Phyto-cannabinoïdes Non-psychotropes* : Les nouvelles Opportunités d'une plante ancienne.(*NdT : non-stupéfiants) Angelo A. Izzo, Francesca Borrelli, Raffaele Capasso, Vincenzo Di Marzo and Raphael Mechoulam Trends in Pharmacological Sciences - CELL Press, 2009, 30, 10, 515-27. doi: 10.1016/j.tips.2009.07.006.   Le Δ9-tetrahydrocannabinol (Δ9THC) se lie aux récepteurs endocannabinoïdes (CB1 et CB2) qui sont activés par les cannabinoïdes endogènes (endocannabinoïdes) et qui sont impliqués dans une large gamme de processus physiopathologiques (exemple: modulation de la libération de neurotransmetteurs, régulation de la perception de la douleur, régulation des fonctions cardiovasculaires, gastro-intestinales et hépatiques). Les effets psychotropes bien connus du Δ9THC qui sont véhiculés par l'activation des récepteurs CB1 [...]

Lire la suite

Variétés de Cannabis, Docteur Ethan Russo, IACM

Variétés de Cannabis: Par Docteur Ethan Russo http://www.cannabis-med.org/index.php?tpl=faq&red=faqlist&id=172&lng=fr   Les consommateurs de cannabis ont souvent indiqué que les différentes variétés de cannabis produisent des effets variables, que se soit concernant les effets psychoactifs ou les bénéfices thérapeutiques. Les variétés sont généralement désignées comme étant soit Sativa, soit Indica, soit hybrides. Or, ces noms, d’un point de vue commercial, prêtent à confusion. Pour cette raison, la communauté scientifique s’est concentrée sur le Tétrahydrocannabinol (THC) qu’elle considérait comme la principale variable et la seule d’importance. En parallèle, jusqu’à très récemment, les croisements sélectifs des variétés de cannabis, destiné à l’usage récréatif ou à l’usage thérapeutique, [...]

Lire la suite

Cannabis – from cultivar to chemovar, A. Hazekamp and J. T. Fischedick, 2012

Cannabis - from cultivar to chemovar A. Hazekamp and J. T. Fischedick Drug Testing and Analysis, 2012, (wileyonlinelibrary.com) DOI 10.1002/dta.407, Copyright © 2012 John Wiley & Sons, Ltd.   Abstract : The medicinal use of Cannabis is increasing as countries worldwide are setting up official programs to provide patients with access to safe sources of medicinal-grade Cannabis. An important question that remains to be answered is which of the many varieties of Cannabis should be made available for medicinal use. Drug varieties of Cannabis are commonly distinguished through the use of popular names, with a major distinction being made between Indica and Sativa types. Although more than [...]

Lire la suite

Cannabis, from plant to pill, Pr Christopher GROF, British Journal of Clinical Pharmacology, 2018, 84, 2463-2467

REVIEW-THEMED ISSUE Cannabis, from plant to pill Pr Christopher GROF, British Journal of Clinical Pharmacology, 2018, 84, 2463-2467 Correspondence Professor Christopher P. L. Grof, School of Environmental and Life Sciences, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia. Tel.: + 61 2 49215858; Fax: +61 2 4921 5361; 1 Centre for Plant Science, School of Environmental and Life Sciences, University of Newcastle, Newcastle, NSW 2308, Australia and 2 The Australian Centre for Cannabinoid Clinical and Research Excellence Hunter Medical Research Institute, Locked Bag 1000, New Lambton, NSW2305, Australia   Keywords : cannabinoids, cannabis, flos, flower, terpenoids   The therapeutic application of cannabis is attracting substantial public and clinical interest. [...]

Lire la suite

Cannabis and the Anxiety of Fragmentation – A Systems Approach for Finding an Anxiolytic Cannabis Chemotype, B. S. Kamal et al., 2018

Cannabis and the Anxiety of Fragmentation - A Systems Approach for Finding an Anxiolytic Cannabis Chemotype, B. S. Kamal, F. Kamal, D. E. Lantela, Frontiers in Neuroscience, 2018, 12, article 730. https://doi.org/10.3389/fnins.2018.00730   Abstract : Cannabis sativa is a medicinal herb with a diverse range of chemotypes that can exert both anxiolytic and anxiogenic effects on humans. Medical cannabis patients receiving organically grown cannabis from a single source were surveyed about the effectiveness of cannabis for treating anxiety. Patients rated cannabis as highly effective overall for treating anxiety with an average score of 8.03 on a Likert scale of 0 to 10 (0 = not effective, [...]

Lire la suite

Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis Sativa Plants from Different Chemotypes, O. Aizpurua-Olaizola, U. Soydaner, E. Oztürk, D. Schibano et al., Journal of Natural Products, février 2016

J Nat Prod. 2016 Feb 26;79(2):324-31. doi: 10.1021/acs.jnatprod.5b00949. Epub 2016 Feb 2. Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes. Aizpurua-Olaizola O1,2, Soydaner U1, Öztürk E1, Schibano D1, Simsir Y1, Navarro P2, Etxebarria N2, Usobiaga A2. Author information 1 Aifame GmbH , Tüfi 450, 9105 Wald-Schönengrund, Switzerland. 2 Analytical Chemistry Department, University of the Basque Country (UPV/EHU) , Barrio Sarriena s/n, 48940 Leioa, Spain. Abstract The evolution of major cannabinoids and terpenes during the growth of Cannabis sativa plants was studied. In this work, seven different plants were selected: three each from chemotypes I and III [...]

Lire la suite